Search

Your search keyword '"Falo C"' showing total 116 results

Search Constraints

Start Over You searched for: Author "Falo C" Remove constraint Author: "Falo C"
116 results on '"Falo C"'

Search Results

2. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

3. 169P A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results

4. 218P Characteristics and outcomes of HER2-low (H-Low) and HER2-zero (H-0) advanced breast cancer (ABC) patients (pts) from GEICAM/2014-03 (RegistEM) registry

5. 11P Independent validation of the HER2DX assay in HER2-positive (HER2+) breast cancer (BC) treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): A correlative analysis from the BiOnHER study

6. Axillary Nodal Management in the setting of Neoadjuvant Chemotherapy

8. Risk factors for lymphedema after breast surgery: A prospective cohort study in the era of sentinel lymph node biopsy

9. Risk Factors for Lymphedema After Breast Surgery: a Prospective Cohort Study in the Era of Sentinel Lymph Node Biopsy

10. 14P Immunomodulatory effect of denosumab in early breast cancer: Preliminary results of a randomized window-opportunity clinical trial D-Biomark

11. Mutational profile from circulating tumor DNA in triple negative breast cancer: Results from the prospective registry of unresectable locally advanced or metastatic breast cancer GEICAM/2014-03 (RegistEM)

14. 289P Results of the window-of-opportunity clinical trial D-BIOMARK: Study of biomarkers of the antitumor activity of denosumab and its role as a modulator of the immune response in early breast cancer

15. 149P Assessing the effect of single dose trastuzumab and pertuzumab (HP) on biological changes and pathological complete response (pCR) in ERBB2+ Breast Cancer: Results from the neoadjuvant BionHER study

16. Risk factors for lymphedema after breast surgery: A prospective cohort study in the era of sentinel lymph node biopsy.

19. Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals

20. Residual cancer burden as a prognostic factor in a large series of neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes

21. Abstract P5-15-09: Impact of oncotype dx genetic signature used in early breast cancer. Clinical and economic analisys of a 110 patient cohort treated in the Catalan Oncologic Institute (ICO), Spain

22. Abstract P3-13-07: Is radiofrequency ablation better than lumpectomy for margin status in breast cancer? Results of a randomized clinical trial

23. Abstract P2-08-58: Prognostic factors of survival in node positive breast cancer patients after neoadjuvant chemotherapy in a large series after 5y follow-up: Can response overcome the poor prognosis of nodal stage?

24. ‘Real world data’ of genomic sequencing for personalised therapy

25. Predictive factors for considering to avoid axilar lymphadenectomy in selected node positive breast cancer patients after neoadjuvant chemotherapy

26. Evaluation of tumor-infiltrating lymphocites (TIL) and response to neoadjuvant chemotherapy according to RCB index in a series of 157 breast cancer cases

27. Abstract P2-09-11: PAM50 intrinsic subtyping as a predictor of pathological complete response to neoadjuvant trastuzumab-based chemotherapy in early HER2-positive breast cancer

28. Abstract P5-21-23: Evaluation of the drug interaction potential of palbociclib and exemestane – Results from the PEARL pharmacokinetic sub-Study

29. Abstract P4-08-08: Biomarkers to predict distant recurrence free survival after neoadjuvant endocrine therapy in breast cancer. A long follow up retrospective study

30. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

32. Abstract P4-21-32: Treatment of early HER2-positive breast cancer in trastuzumab era in everyday clinical practice: An overview after 10 years of its approval

33. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

37. Abstract P2-08-31: Tumor and axillar downstaging as a prognostic factor and evaluation of effectiveness to primary chemotherapy in breast cancer: A retrospective analysis

38. Abstract P6-11-04: Use of Mammaprint© (MMP) genetic signature in early breast cancer patients. Economic analisys of a 129 patient cohort treated in three Spanish hospitals

Catalog

Books, media, physical & digital resources